The research of Hans-Peter Kiem, MD, PhD has focused on stem cell and transplantation biology, cell and gene therapy, and the development and use of novel gene-editing technologies. The overall goal has been the development of improved treatment approaches for patients with genetic and infectious diseases and cancer, in particular, hematologic malignancies. He is a clinically active hematologist/oncologist seeing patients on the marrow transplant, immunotherapy, and MDS/AML service. Hans-Peter has extensive experience training students and postdoctoral fellows and has mentored more than 50 trainees in his lab over the past 20 years. Many of his trainees now hold tenured faculty positions in the U.S. and Germany. Hans-Peter has been the Sponsor of four clinical gene therapy studies (HIV, glioblastoma, and Fanconi anemia) and he is the PI or Co-PI of many R01 or Program Project grants. Hans-Peter has also served on the NIH Recombinant DNA Advisory Committee (RAC) for five years, the last year as Chair, and served as the Chair of the Stem Cell Committees for both the American Society for Gene and Cell Therapy (ASGCT) and the American Society of Hematology.
Hans-Peter received his MD and PhD degrees from the University of Ulm in Germany and then joined Dr. Karl Blume’s research group at Stanford University as a research fellow, working with Drs. Sklar and Cleary to study molecular abnormalities and minimal residual in patients with lymphoma (Oncogene 1990; Blood 1991) and with Drs. Weissman and Negrin on the use of a novel immunodeficient mouse model for lymphoma (J. Exp. Med. 1991). After a two-year fellowship at Stanford, Hans-Peter went on to complete his residency in Internal Medicine and his Physician/Scientist training at Vanderbilt University. He joined the Fred Hutchinson Cancer Research Center in 1992, where he completed his clinical fellowship in Oncology.